Orthopedics

Your Article Summary

See Latest Articles

Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass
Osteoporosis International, 10/06/09

Downs Jr RW et al. – Arzoxifene suppressed bone turnover and increased BMD. Within the limitations of this study, the endometrial safety profile of arzoxifene appeared similar to that of raloxifene. While no clear dose effect was evident, arzoxifene 20 and 40 mg/day appeared the optimal doses for reducing bone turnover.

• Postmenopausal women with T-score between ?1 and ?2.5 were randomly assigned to daily arzoxifene 5, 10, 20, or 40 mg, raloxifene 60 mg, or placebo
• All received daily calcium

• Arzoxifene doses significantly reduced osteocalcin (primary endpoint), type 1 collagen C-telopeptide, bone specific alkaline phosphatase, and procollagen type I amino-terminal propeptide versus placebo, and increased lumbar spine BMD
• Arzoxifene generally had greater effects on bone turnover and BMD than raloxifene
• Arzoxifene decreased cholesterol, LDL cholesterol, and fibrinogen versus placebo
• Endometrial thickness change with arzoxifene not significantly different from placebo or raloxifene
• No cases of endometrial hyperplasia or adenocarcinoma observed
• Adverse event reporting with arzoxifene similar to that with raloxifene, as were hot flush and night sweat reporting

Today in Bone Metabolism...keeping you current

Receive free subspecialty "5-minute updates" via email

The association between osteoporosis and static balance in elderly women
Osteoporosis International, 11/27/09

Bone loss and the risk of non-vertebral fractures in women and men: The Tromsø study
Osteoporosis International, 11/27/09

The Role of Quantitative Bone Scanning in the Assessment of Bone Turnover in Patients with Charcot Foot
Diabetes Care, 11/25/09

 See all of Bone Metabolism